Inactive Instrument

Press Releases Celladon Corp Nasdaq

Equities

US15117E1073

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection	Apr. 01	AQ
Eiger and Partner, AnGes, Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 19	AQ
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	Jan. 18	PR
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split	Jan. 04	PR
Eiger BioPharma: Q3 Earnings Snapshot	Nov. 09	AQ
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 09	PR
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta	23-09-12	PR
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference	23-09-05	PR
Eiger BioPharma: Q2 Earnings Snapshot	23-08-14	AQ
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-14	PR
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide, David Apelian Takes Helm as CEO	23-06-30	AQ
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO	23-06-29	PR
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow	23-06-28	PR
Eiger BioPharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K	23-06-20	PU
EIGER BIOPHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-06-20	AQ
Eiger BioPharma: Q1 Earnings Snapshot	23-05-11	AQ
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update	23-05-11	PR
Eiger BioPharmaceuticals Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	23-05-04	AQ
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)	23-05-03	PR
EIGER BIOPHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	23-04-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celladon Corp Nasdaq

Equities

US15117E1073

Press Releases

Filters